News

Biosenta confirms that the management is unaware of any material change that would account for the recent increase in market activity.

Biosenta’s stock closed at 0.75 CAD +0.37 (97.37%). This is in step with Biosenta’s strategic business plan grow the company.

This partnership enables the University team to research nanoparticles for use as antimicrobial filler in commercial construction materials.

A strategic licensing partnership with Kleen Bee Labs was finalized today. This license will give the rights for distribution of DualXtiv.